Table 4.

Clinical trials using semaphorins/semaphorin receptors as targets for the therapy of cancer

ClinicalTrials.gov Identifier	Recruitment status	Aim of the trial	Cancer histotype
NCT01313065 Phase 1	Completed	Safety, tolerability, pharmacokinetics and pharmacodynamics of anti-Semaphorin 4D neutralizing monoclonal antibody, VX15/2503 (Pepinemab)	Advanced solid tumors (Patnaik A et al Clin Cancer Res 2016)
NCT03268057	Completed	Safety and tolerability of VX15/2503 in combination with avelumab	Advanced non-small cell lung cancer
Phase 1, Phase 2
NCT03690986	Recruiting	Efficacy of VX15/2503 in combination with ipilimumab or nivolumab	Stage I-IVA head and neck squamous cell cancer
Phase 1
NCT03373188	Recruiting	Efficacy of VX15/2503 with or without ipilimumab or nivolumab	Resectable stage I-III pancreatic and stage IV colorectal cancer
Phase 1
NCT03769155	Recruiting	Efficacy of VX15/2503 with or without ipilimumab and/or nivolumab	Resectable Stage IIIB-D Melanoma
Phase 1
NCT03425461	Active, not recruiting	Efficacy of VX15/2503 with nivolumab or ipilimumab	Stage III or IV Melanoma
Phase I
NCT00747734	Completed	Dose-limiting toxicities of anti-Neuropilin1 neutralizing monoclonal antibody, MNRP1685A	Locally advanced or metastatic solid tumors (Weekes CD et al Invest New Drugs 2014)
Phase 1
NCT00954642	Completed	Efficacy of MNRP1685A in combination with bevacizumab with or without paclitaxel	Locally advanced or metastatic solid tumors (Patnaik A et al CancerChemotherapyPharmacology 2014)
Phase 1